Content area
Full Text
Biophan Technologies, Inc., a developer of next-generation medical technology, has announced that a new round of experimental tests have demonstrated the ability of the company's proprietary technology to enable Magnetic Resonance Imaging (MRI) of Vena Cava filters. Vena Cava filters are implanted in the Vena Cava of some patients undergoing surgery to capture and trap blood clots that have the potential to cause embolisms.
These mobile blood clots are one of the most common potentially fatal complications for patients undergoing surgery. Vena Cava filters are implanted in the inferior Vena Cava, a large vein that carries blood to the heart, to prevent blood clots released during surgery from causing pulmonary embolisms; the filters can be left in place in the blood vessels on either a temporary or permanent basis. Doctors image the filters after surgery to determine if they have captured thrombotic material, and to determine when it is safe to remove the filter. Biophan's pioneering technology significantly improves the ability of doctors to image within the filters using MRI.
Biophan has announced the online availability of a slide presentation that demonstrates the clear and useful MRI images of Vena Cava filters that the company's proprietary AMRIS technology now makes possible. Biophan's patented technology is the first solution to enable the production of Vena Cava filters that can be accurately imaged by MRI; existing Vena Cava filters...